RBC Capital Reiterates Sector Perform on Design Therapeutics, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has reiterated a Sector Perform rating on Design Therapeutics (NASDAQ:DSGN) and maintained a $4 price target.
August 06, 2024 | 12:52 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital has reiterated a Sector Perform rating on Design Therapeutics and maintained a $4 price target.
The reiteration of a Sector Perform rating and maintenance of the $4 price target by RBC Capital suggests a neutral outlook for Design Therapeutics in the short term. This indicates that the stock is expected to perform in line with the sector, and there are no significant changes in the analyst's view.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100